Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (387)	11/17/1998 10:34:00 PM
From: JMarcus	Read Replies (1) \| Respond to of 1494

At the meeting, Lisa Carr explained some of the science behind Memantine and AIDS-related dementia. Frankly, it went over my head and I'm not sure that I wrote down the nomenclature correctly. Please correct any errors in what follows: NMDA-receptors are implicated as a primary pathway for qp-120 induced neurotoxicity, which is itself implicated in AIDS-related dementia. Memantine has been shown to prevent qp-120 induced neurotoxicity in cell cultures. In preclinical trials, Memantine has also been shown to reduce neurotoxic effects in mice that over express qp-120 in the brain. What I believe this means is that Memantine's mechanism of action in treating AIDS-related dementia is understood.